trial summary · NCT07728175
Effects of Sirolimus on Asymptomatic ApoE4 Carriers
Effects of Sirolimus on Middle Aged Asymptomatic ApoE4 Carriers
Trial record from the TrialBase DB dataset, status RECRUITING, condition Genetic Predisposition to Disease, sponsored by University of Missouri-Columbia. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure. Sirolimus (Rapamycin) is an FDA-approved medication which may improve the blood flow to the brain. The purpose of the clinical trial is to find out whether sirolimus can help improve blood flow and energy use in the brain in women ages 45 to 65 who have the ApoE4 gene, a gene which increases the risk of developing Alzheimer's disease later in life. There will be two arms in this trail, a sirolimus arm and a placebo arm. A placebo is a pill that looks like the study drug, but it does not have any real medicine in it. Participants will be randomized to one arm or the other, but not to both arms. Three study visits over a 12-week period are required. Participants will: (i) Complete some questionnaires about how well you think; (ii) Complete genetic testing for the ApoE4 gene; (iii) Have blood work, blood pressure and height and weight collected; (iv) Take either Sirolimus or a placebo daily, by mouth, for approximately 4 weeks; (v) Keep a diary of when the sirolimus or placebo is taken; (vi) Complete 2 Magnetic Resonance Imaging (MRI) exams
Source record: https://clinicaltrials.gov/study/NCT07728175
Facts
| registry id | NCT07728175 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Genetic Predisposition to Disease |
| sponsor | University of Missouri-Columbia |
| sponsor class | OTHER |
| enrollment | 225 |
| start date | 2026-12-01 |
| primary completion | 2027-12-31 |
| completion | 2028-07-07 |
| results posted | not reported |
Conditions
- Genetic Predisposition to Disease
- Healthy Volunteer
- APOE-4 Positive
Interventions
- Sirolimus (rapamycin)
- Placebo
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.